Sequential Multiple Assignment Treatment for Bipolar Disorder (SMART)

Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder

The purpose of this study is to compare which of the two mood stabilizers (drugs that help to steady/stabilize mood in patients with bipolar disorder (BD)), lithium and divalproex, is more effective in patients with bipolar disorder over 26 weeks. The study will also compare if lithium or divalproex used alone versus lithium or divalproex used with quetiapine versus lithium or divalproex used with lamotrigine is more effective when symptoms of depression develop.

Study Overview

• Status: Completed
• Conditions: Bipolar I Disorder; Bipolar II Disorder
• Intervention / Treatment: Drug: Lithium; Drug: Divalproex; Drug: Quetiapine; Drug: Lamotrigine

Detailed Description

This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers (MS), lithium [Li] or divalproex [Div]. Those who develop protocol defined depression will then be randomized to a MS alone, MS + quetiapine [QTP] or MS + lamotrigine [LTG]. A SMART strategy employs a rule for adding new treatments based on each patient's current illness state and response during the trial, mimicking the adaptive nature of treatment selection which occurs in clinical settings, but in a controlled way which allows application of causal inference. By using early indices of response to dynamically alter treatment decisions to improve outcome, SMART eliminates unmeasured confounders associated with treatment decisions that are not randomized, as occurs in data mining exercises and in other non-randomized decisions in studies which randomize one variable at baseline. This sequential adaptive design represents a methodological innovation in bipolar trial history which will have particular implications for effectiveness studies.

Specific Aim A.1: Assess the feasibility of a SMART design in the conduct of an effectiveness study over 26 weeks in patients with BD (bipolar disorder).

Aim A.2 Compare the effectiveness of Li to Div as a primary component of treatment for BD over 26 weeks.

Aim A.3: Assess the effectiveness of MS + QTP and MS + LTG versus MS in subjects who develop depression.

A4. Exploratory Aims: 1.Determine the effects of ethnicity, language facility, education and stress as moderators of treatment outcomes; 2. Explore the use of novel statistical methodologies to more informatively characterize illness trajectories in response to the interventions. In the aggregate these aims also will clarify whether the SMART confirms results provided by traditional, single point randomized controlled trials (RCTs).

• Study Type: Interventional
• Enrollment (Actual): 112
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • Case Western Reserve University
  • Texas
    • San Antonio, Texas, United States, 78229-3900
      • University of Texas Health Science Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• DSM-IV TR (Diagnostic and Statistical Manual Edition IV Text Revision) diagnosis BD I or II as assessed by MINI PLUS (Mini International Neuropsychiatric Interview PLUS)
• Male or female ≥ 18 years old
• Currently symptomatic with a CGI-BP-S ≥3 for mania/hypomania &/or depression for ≥ 2 weeks
• One of the following indicators of recent active illness: a depressive or manic or hypomanic or mixed episode in the past 12 months
• If female of child bearing age must use effective birth control.

Exclusion Criteria:

• Unwilling or unable to comply with study requirements
• Renal impairment (serum creatinine > 1.5 mg/dL)
• If maintained on thyroid medication must be euthyroid for at least 1 month before Visit 1
• Patients who have had intolerable side effects to QTP, Li, Div, or LTG
• Patients whose clinical status requires inpatient care
• Drug/alcohol dependence within the past 30 days
• Pregnancy as determined by serum pregnancy test or breastfeeding
• History of poor response to Li at a serum Li of ≥ 0.5 mEq/L (milliequivalents per Liter) or Div at a serum level of ≥ 45 mg/dL for at least 2 weeks.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Lithium; This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, lithium [Li] at baseline. Lithium is one of these two mood stabilizers. The person may or may not stay solely on lithium throughout the study.	Drug: Lithium; Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).; Other Names: Lithium Carbonate
Active Comparator: Divalproex; This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, divalproex (DV)at baseline. Divalproex is one of these two mood stabilizers. The person may or may not stay solely on divalproex throughout the study.	Drug: Divalproex; DV will be dosed to attain DV levels of ≥45mg/L.; Other Names: Depakote; Depakote ER
Active Comparator: Lithium plus Quetiapine; Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + quetiapine [QT].	Drug: Lithium; Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).; Other Names: Lithium Carbonate; Drug: Quetiapine; QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.; Other Names: Seroquel
Active Comparator: Lithium plus Lamotrigine; Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + lamotrigine (LM).	Drug: Lithium; Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).; Other Names: Lithium Carbonate; Drug: Lamotrigine; LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.; Other Names: Lamictal
Active Comparator: Divalproex plus Quetiapine; Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + quetiapine [QT].	Drug: Divalproex; DV will be dosed to attain DV levels of ≥45mg/L.; Other Names: Depakote; Depakote ER; Drug: Quetiapine; QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.; Other Names: Seroquel
Active Comparator: Divalproex plus Lamotrigine; Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + lamotrigine (LM).	Drug: Divalproex; DV will be dosed to attain DV levels of ≥45mg/L.; Other Names: Depakote; Depakote ER; Drug: Lamotrigine; LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.; Other Names: Lamictal

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bipolar Inventory of Symptoms Scale (BISS)	The BISS uses a structured interview to assess the full spectrum of symptoms associated with all primary clinical states in bipolar disorder, yielding a total severity, a depression, a mania, as well as dimensional scale scores. There are 42 items; each item is rated on a 0-4 scale. The BISS is a clinician-rated instrument. The Scale is rated as follows: 0 Not at all; Slight; Mild; Moderate; Severe Each of the 42 items is rated separately, with a score, based on the most recent 7 day period. The mean score is calculated from the total score, giving an overall score out of 4, where 0 is slight and 4 is the most severe symptoms. A negative score indicated an improvement from baseline to 26 weeks.	Change from Baseline to 26 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Global Assessment of Functioning	The Clinical Global Impression-Severity Scale (CGI-S) is used to assess global illness severity The CGI-S score change is measured from baseline to 26 weeks and is rated on a 7-point scale. The scale is read as follows: very much improved since the initiation of treatment; much improved; minimally improved; no change from baseline (the initiation of treatment); minimally worse; much worse; very much worse since the initiation of treatment The score is calculated as a mean of all items, where 1 indicates improvement from inititation of visit, and 7 indicates the condition to be much worse since the inititation of treatment. A negative score indicates a change from worse to better.	Change from Baseline to 26 weeks
Baseline Randomization Percentage of Bipolar Types	Percentages of Type I and Type II Bipolar Disorder included in Randomization groups	Baseline
Demographic in Randomization 1 Group	Baseline demographic percentages of subject randomized to either Divalproex or Lithium at the first randomization	Baseline

Collaborators and Investigators

• Sponsor: The University of Texas Health Science Center at San Antonio
• Collaborators: National Institute of Mental Health (NIMH)
• Investigators: Principal Investigator: Charles L. Bowden, M.D., University of Texas; Principal Investigator: Joseph R Calabrese, M.D., Case Western Reserve University

Publications and helpful links

General Publications

• Hashimoto Y, Kotake K, Watanabe N, Fujiwara T, Sakamoto S. Lamotrigine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2021 Sep 15;9(9):CD013575. doi: 10.1002/14651858.CD013575.pub2.

Study record dates

Study Major Dates

• Study Start: June 1, 2011
• Primary Completion (Actual): December 1, 2016
• Study Completion (Actual): December 1, 2016

Study Registration Dates

• First Submitted: February 29, 2012
• First Submitted That Met QC Criteria: April 30, 2012
• First Posted (Estimate): May 1, 2012

Study Record Updates

• Last Update Posted (Actual): August 19, 2020
• Last Update Submitted That Met QC Criteria: August 17, 2020
• Last Verified: August 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Bipolar and Related Disorders; Disease; Bipolar Disorder; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Enzyme Inhibitors; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Membrane Transport Modulators; Antidepressive Agents; GABA Agents; Anticonvulsants; Sodium Channel Blockers; Antimanic Agents; Calcium-Regulating Hormones and Agents; Calcium Channel Blockers; Lamotrigine; Valproic Acid; Quetiapine Fumarate; Lithium Carbonate
• Other Study ID Numbers: HSC20110361H; 1P30MH086045-01A2 (U.S. NIH Grant/Contract)